SCHEMBL234520

SCHEMBL234520

CCN(CC)C(=O)Nc1ccccc1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.58
NPC1 O15118 1/20 0.58
HPGD P15428 5/20 0.56
ALDH1A1 P00352 1/20 0.56
ABCC1 P33527 2/20 0.55
ALOX12 P18054 1/20 0.53
POLB P06746 1/20 0.51
ITGB3 P05106 1/20 0.50
ITGB1 P05556 1/20 0.50
ITGAV P06756 1/20 0.50
ITGA5 P08648 1/20 0.50
PGR P06401 1/20 0.49
SCN1A P35498 1/20 0.49
SCN2A Q99250 1/20 0.49
SCN3A Q9NY46 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HDAC3 O15379 1/20 0.49
HDAC4 P56524 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC7 Q8WUI4 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10434939 0.85 ABCC1 (0.54) RAB9ANPC1HPGDALDH1A1ABCC1
SCHEMBL13930306 0.84 RAB9A (0.56) RAB9ANPC1HPGDALDH1A1ABCC1
SCHEMBL11136745 0.83 MEN1 (0.59) RAB9ANPC1HPGDALDH1A1ALOX12
SCHEMBL8217293 0.83 GUSB (0.56) RAB9ANPC1HPGDALDH1A1ALOX12
SCHEMBL7256367 0.82 ABCC1 (0.55) RAB9ANPC1ABCC1POLBLMNA
SCHEMBL11139406 0.81 ALDH1A1 (0.63) RAB9ANPC1HPGDALDH1A1ABCC1
SCHEMBL30734411 0.81 ALDH1A1 (0.63) RAB9ANPC1HPGDALDH1A1ABCC1
SCHEMBL29052342 0.81 MEN1 (0.53) RAB9ANPC1HPGDALDH1A1PGR
SCHEMBL234056 0.81 SMN1; SMN2 (0.59) RAB9ANPC1ALDH1A1ABCC1SMN1; SMN2
SCHEMBL16599594 0.81 ABCC1 (0.54) RAB9ANPC1HPGDALDH1A1ABCC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362067-B2 3-aminoalkyl-1,3-dihydro-2H-indol-2-one derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-01-29 US disclosed
EP-2265582-B1 NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF. SANOFI SA (FR) 2012-01-04 EP disclosed
CN-102015642-A Novel 3-aminoalkyl-1, 3-dihydro-2H-indol-2-one derivatives, preparation method and therapeutic use thereof SANOFI AVENTIS 2011-04-13 CN disclosed
US-20110059955-A1 NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-10 US disclosed
EP-2265582-A1 NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF. Sanofi-Aventis (FR) 2010-12-29 EP disclosed
WO-2009115685-A1 NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF. SANOFI-AVENTIS (FR) 2009-09-24 WO disclosed
US-3956237-A HINDERED UREA OR THIOUREA THE DOW CHEMICAL COMPANY (US) 1976-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059955-A1 NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF AVPR1B, AVPR1A, AVPR2 RAB9A 947/4885NPC1 3727/4885HPGD 651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.